Clinical Trial Management System Market - Forthcoming Trends to Boost Global Revenue Growth

Recent Developments in the Global Clinical Trial Management Systems Market:

# In November 2017, Bio-Optronics and Complion entered into a partnership in order to integrate and develop their solutions, namely, CTMS and eRegulatory Solutions.

# In September 2017, Pamplona completed the acquisition of Paraxel and bought its shares in order to help PARAXEL increase its productivity.

# In May 2017, Oracle opened its Oracle Cloud EU Region in Germany, with the addition of modern infrastructure as a service (IaaS) architecture and new IaaS and platform as a service (PaaS) cloud services.

# In January 2017, MedNet Solutions released the latest version of iMedNet with enhanced features.

# In June 2016, Bio-Optronics launched the latest version of the Clinical Conductor CTMS.

The global clinical trial management system (CTMS) market is expected to reach USD 1,065.6 million by 2022 from USD 590.0 million in 2017, at a CAGR of 12.6%.

The major factors driving the growth of the CTMS market include the significant partnerships between Asian CROs and pharma companies, rising number of clinical trials in both developing and developed nations, availability of advanced and upgraded CTMS solutions, and rising government support for clinical trials in Asian countries.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=470

The pharmaceutical and biopharmaceutical companies segment is expected to hold the largest share of the market in 2017

By end user, the CTMS market is segmented into pharmaceutical and biopharmaceutical companies, contract research organizations, medical device companies, and others. The pharmaceutical and biopharmaceutical companies segment is further subsegmented into large pharmaceutical companies and mid-small pharmaceutical companies.

The pharmaceutical and biopharmaceutical companies segment is expected to account for the largest share of the CTMS market in 2017. The largest share is attributed to the increasing adoption of CTMS software during drug clinical trials by pharmaceutical and biopharmaceutical companies.

Key questions addressed in the report:

# What are the growth opportunities related to CTMS market across major regions in the future?

# Emerging countries have immense opportunities for the growth and adoption of enterprise CTMS products. Will this scenario continue in the next five years?

# What are the various types of CTMS products and their market share in the overall market?

# What are the new trends and advancements in the clinical trials industry?

North America is expected to dominate the CTMS market during the forecast period

Geographically, the Clinical Trial Management System Market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America is expected to account for the largest share of the global CTMS market during the forecast period (2017-2027). Factors such as rising number of on-going clinical trials (especially in the US), presence of leading players from both demand and supply sides, and government funding for clinical research are contributing to the large share of the North American region.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=470

Analysis of the market developments between 2014 and 2017 revealed that several growth strategies such as product launches, enhancements, strategic acquisitions, agreements, partnerships, collaborations, and expansions were adopted by the market players to strengthen their product portfolios and maintain a competitive position in the Clinical Trial Management Systems Market.

Among these business strategies, product enhancements, agreements, and partnerships were the most widely adopted growth strategies by the players in the CTMS market.

As of 2016, the global clinical trial management systems market was dominated by Oracle Corporation (US), Medidata Solutions, Inc. (US), PAREXEL International Corporation (US), Bioclinica. (US), Bio-Optronics, Inc. (US), IBM (US), DATATRAK (US), Veeva Systems (US), DSG (US), MasterControl (US), ERT (US), Forte Research Systems (US), MedNet Solutions (US), ArisGlobal (US), and DZS Software Solutions (US).

Cell Viability Assays Market - Emerging Industry Dynamics and Future Forecasts

Factors such as rising incidence and prevalence of chronic and infectious diseases, growing availability of funds for research and rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics are driving the growth of this market.

The global cell viability instruments market is projected to reach USD 4.16 billion by 2023 from USD 2.78 billion in 2018, at a CAGR of 8.4%.

The emerging markets are expected to provide growth opportunities for players operating in the cell viability assays market in the coming years. However, the high cost of instruments is expected to restrain the growth of this market to a certain extent during the forecast period.

Target Audience:

# Manufacturers of cell viability instruments and consumables

# Distributors of cell viability instruments and consumables

# Research and development organizations

# Hospitals and clinics

# Diagnostic centers

# Market research and consulting firms

# Venture capitalists and investors

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=5932511

By product, the consumables segment is expected to account for the largest share of the cell viability assays market in 2018

On the basis of product, the consumables segment is expected to account for the largest share of the cell viability assays market in 2018. This large share can be attributed to the repeated consumption of consumables in various cell viability procedures.

The growing focus on stem cell and cancer research is another major driver for the growth of the cell viability consumables market along with the growing application of cell viability in quality control procedures in various industries, such as food and beverage, pharmaceutical, biotechnology products manufacturing, environmental monitoring, and water treatment.

Major Objectives of the Study:

# To define, describe, segment, and forecast the global cell viability assays market by product, application, cell type, end user, and region.

# To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges).

# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.

# To forecast the size of the cell viability assays market in five main regions (along with major countries) North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

# To profile key players in the global cell viability assays market and comprehensively analyze their core competencies and market shares.

By end user, the pharmaceutical and biotechnology companies segment is estimated to hold the largest share of the cell viability assays market in 2018

On the basis of end user, the cell viability instruments market is segmented into pharmaceutical and biotechnology companies, hospital and diagnostic laboratories, academic and research institutes, and other end users (food and beverage companies and environmental testing companies).

The pharmaceutical and biotechnology companies segment is expected to account for the largest share in 2018. The large share of this segment can be attributed to the increasing number of R&D activities undertaken by these companies for the development of biopharmaceutical products.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=5932511

North America to dominate the market in 2018

North America is expected to account for the largest share of the cell viability assays market in 2018, followed by Europe and Asia Pacific. The growing incidence rate of various infectious diseases, investment initiatives by the government, and the high-quality infrastructure for clinical and laboratory research are the major factors responsible for the large share of the North American cell viability assays market. Moreover, a number of major global players are based in the US, owing to which, the US is a center for innovation in the cell viability assays market.

Major Leaders:

Players in the global cell viability instruments market, such as Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), GE Healthcare (US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), G-Biosciences (US), Creative Bioarray (US), Danaher Corporation (US), and Becton, Dickinson and Company (US), are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies of product launches, expansions, agreements, collaborations, and acquisitions.

ATP Assay Market to Witness Major Revenue Growth by 2024

Research Methodology Used for ATP Assay Instruments Market Size:

Primary Research:

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing & sales directors, technology & innovation directors, and related key executives from various key companies operating in the ATP assays market.

Secondary Research:

In the secondary research process, various secondary sources such as D&B Hoovers, Bloomberg Business, and Factiva have been referred to identify and collect information for this study. These secondary sources included annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold standard & silver standard websites, regulatory bodies, and databases.

The global ATP assay instruments market size is projected to reach USD 315 million by 2024 from USD 191 million in 2019, at a CAGR of 10.5%.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223438780

Growth in this market is majorly driven by the increasing demand for ATP assays in pharmaceutical & biotechnology companies, rising investments in pharmaceutical & biotechnology R&D, the increasing prevalence of cancer and other chronic and infectious diseases, and the shift from culture-based tests to rapid tests.

Objectives of the study:

# To define, describe, segment, and forecast the ATP assays market based on product, application, end user, and region.

# To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, and opportunities).

# To analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market.

# To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market players.

# To forecast the size of the market in five main regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

# To profile key players in the ATP assays market and comprehensively analyze their core competencies and market shares.

# To track and analyze competitive developments such as mergers, acquisitions, collaborations, agreements, and partnerships reported by leading players in the market.

The consumables & accessories segment accounted for the largest share of the ATP assays market, by product, in 2018

Based on product, the ATP assay instruments market is segmented into consumables & accessories and instruments. The consumables & accessories segment accounted for the largest ATP assays market share in 2018. The large share of this segment can be attributed to the high usage of ATP assays for microbial contamination testing and the growing applications of ATP assays in different industries like the food & beverage industry and agriculture industry. The large share of this segment is also supported by the fact that the consumables such as kits & reagents, microplates, and swabs are purchased repeatedly as compared to instruments such as luminometers and spectrophotometers.

Key Questions Addressed in the Report:

# Which are the top 10 players operating in the ATP assays market?

# What are the drivers, restraints, opportunities, and challenges of the market?

# What are the prevailing industry trends, and what is the current scenario in the market?

# What are the growth trends in the market at the segmental and overall levels?

# How is the market performing in different regions across the globe?

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=223438780

Asia Pacific is expected to witness the highest growth in the ATP assays market from 2019 to 2024

The global ATP assay market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, the Asia Pacific market is estimated to grow at the highest CAGR, as several countries are witnessing a growing number of proteomics, genomics, and stem cell research activities, increasing research funding, rising investments by pharmaceutical & biotechnology companies, and the growing trend of research infrastructure modernization.

The major players adopted various strategies such as partnerships, agreements, mergers, and acquisitions to expand their presence in the global ATP assays market.

Prominent players in this market include Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Lonza Group (Switzerland), Promega Corporation (US), Hygiena, LLC. (US), Agilent Technologies, Inc. (US), Abcam plc. (UK), Danaher Corporation (US), BioThema AB (Sweden), Abnova Corporation (Taiwan), AAT Bioquest (US), PromoCell GmbH (Germany), BioVision, Inc. (US), Biotium (US), Canvax Biotech S.L. (Spain), Creative Bioarray (US), Elabscience (US) and MBL International Corporation (US).

Global Surgical Lasers Industry is Expecting Major Tech Innovations in Near Future

Target Audience:

# Surgical laser product manufacturing companies

# Product suppliers and distributors

# Healthcare service providers [including hospitals, specialty clinics, and ambulatory surgery centers (ASCs)]

# Research laboratories and academic institutes

# Clinical research organizations (CROs)

# Government regulatory authorities

# Independent authorities and non-government organizations

# Market research and consulting firms

# Venture capitalists

The surgical lasers market is expected to reach USD 2.37 Billion by 2021 from USD 1.85 Billion in 2016; growing at a CAGR of 5.1% during the forecast period.

Increasing prevalence of chronic diseases, technological advancements in surgical lasers, increasing incidence and prevalence of targeted diseases, and high prevalence of ophthalmic disorders are the major factors driving the growth of this market. In addition, growing preference for minimally invasive surgeries are further adding to the growth prospects of this market.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12712582

A combination of bottom-up and top-down approaches was used to calculate the sizes and growth rates of the market and its subsegments. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. In this research study, all possible parameters that affect this market have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative & qualitative data.

Primary interviews with key opinion leaders were also used to determine the percentage shares of each product in emerging nations. The report provides qualitative insights about growth rates and market drivers for all subsegments. It maps market sizes and growth rates for each subsegment and identifies segments poised for rapid growth in each geographic region.

Based on procedure type, the market is segmented into open surgery, laparoscopic surgery, and percutaneous surgery. The laparoscopic surgery segment is expected to dominate the market. This growth can be primarily attributed to the procedural benefits of laparoscopic procedures and growing patient awareness and market demand for less-invasive disease therapies.

On the basis of type, the surgical lasers market is categorized into five segments, namely, carbon dioxide (CO2) lasers, argon lasers, Nd:YAG lasers, diode lasers, and other surgical lasers (fiber lasers, dye lasers, Er:YAG lasers, and excimer lasers). The carbon dioxide (CO2) lasers segment is growing at the highest CAGR in the market due to the widespread availability of innovative CO2-based surgical lasers and ongoing technological advancements in cosmetic laser treatment.

North America is expected to hold the largest share of the global surgical lasers market, followed by Europe in 2016. However, the Asia-Pacific market is expected to grow at the highest CAGR from 2016 to 2021. Factors driving market growth in the Asia-Pacific region include the presence of a large patient population for target diseases (coupled with rapidly growing geriatric population), rising awareness among healthcare professionals related to the procedural benefits of surgical laser products, and increasing government initiatives to reduce the burden of ophthalmic disorders.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=12712582

As of 2015, Lumenis (Israel), Cynosure, Inc. (U.S.), Alma Lasers (Israel), IPG Photonics Corporation (U.S.), Abbott Laboratories, Inc. (U.S.), Boston Scientific Corporation (U.S.), Spectranetics Corporation (U.S.), Biolitec AG (Austria), Fotona d.o.o. (Slovenia), and BISON MEDICAL Co., Ltd. (South Korea) are some of the key players operating in the surgical lasers market.

Global Dental Lab Industry is Expected to Grow at a Healthy Rate in the Forecast Period

The rapid growth in the geriatric population and the associated increase in the prevalence of edentulism, growing dental tourism in emerging markets, rising incidence of dental caries and other periodontal diseases, and the increased outsourcing of certain manufacturing functions to dental laboratories.

Objectives of the Study:

# To define, describe, and forecast the global dental laboratories devices market by material, equipment, prosthetic type, and region.

# To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges).

# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.

# To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market players.

# To forecast the size of the dental laboratory market, in five main regions, namely, North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East and Africa.

# To profile key players in the global dental laboratory market and comprehensively analyze their core competencies and market shares.

# To track and analyze competitive developments such as research and development activities; joint ventures, alliances, mergers and acquisitions; new product/technology developments; and agreements, partnerships, and other developments of key players in the market

The dental laboratories market is expected to reach USD 43.08 Billion by 2022 from an estimated USD 32.56 Billion in 2017, at a CAGR of 5.8% during the forecast period.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223694318

By equipment, the milling equipment segment is expected to hold the largest share of the market during the forecast period

Based on equipment, the global dental laboratories market is segmented into milling equipment, scanners, furnaces, and articulators. In 2016, the milling equipment segment accounted for the largest share of the dental laboratories market, this trend is also expected to continue during the forecast period. The growth of this segment can be attributed the increasing use of milling equipment in dental restoration to obtain high precision and accuracy, increasing use of digital manufacturing processes in dentistry, and the increasing demand for fabricating or customizing restoration models in a cost-effective manner.

Years considered for this report:

# 2016 – Base Year

# 2017 – Estimated Year

# 2022 – Projected Year

Europe dominated the market in 2016

Europe accounted for the largest share of the dental laboratories devices market in 2016, followed by North America. The rising geriatric population, increasing dental tourism, growth in the number of dental laboratories, growing government expenditure on oral healthcare across Europe, and presence of higher reimbursement rates for dental procedures in Europe as compared to other regions are the key factors driving the growth of the dental laboratories market in Europe.

Target Audience:

# Dental product manufacturers & distributors

# Dental equipment manufacturers & distributors

# Dental laboratories

# Government associations and dental practitioners

# Market research and consulting firms

# Venture capitalists and investors

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=223694318

Players in the global dental laboratories market, such as DENTSPLY SIRONA Inc. (US), Planmeca Oy (Finland), Ivoclar Vivadent AG (Liechtenstein), VOCO GmbH (Germany), Danaher Corporation (US) are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies.

Zimmer Biomet Holdings, Inc. (US), Mitsui Chemicals, Inc. (Japan), Septodont Holding (France) are players focusing on organic growth strategies like product launches to enhance their market presence.

Investigational New Drug Requirements for Fecal Microbiota Boosts Major Tech Innovations in Global Human Microbiome Research

The study involved two major activities in estimating the current market size of the human microbiome market. Exhaustive research was conducted to collect information on the market as well as its peer and parent markets.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

This Study Will Also Help You With the Details on:

# Covid Impact on Human Microbiome Market, growth/decline in product type/use cases of Human Microbiome Market due to cascaded impact of Covid on Extended Ecosystem.

# How top 50 companies in Human Microbiome Market are making rapid shifts in their strategies as we speak here.

# Outside-in view of top 50 companies client and client’s clients shifting short-term priorities.

Microbiomes are responsible for a wide variety of metabolic and developmental processes—from food digestion to vitamin synthesis and even brain function. They also play a major role in human conditions, such as obesity and inflammatory bowel disease.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and detailed research on the human microbiome is restraining the growth of this market.

The global human microbiome market is projected to reach USD 1,731 million in 2027 from USD 942 million in 2024, at CAGR of 22.5 % during the forecast period.

The infectious diseases segment to account for the largest share of the market in 2022

Based on disease, the human microbiome market is segmented into five categories—infectious diseases, endocrine & metabolic disorders, inflammatory diseases, cancer, and other diseases. The infectious disease segment is expected to dominate the market in 2022. This is due to the increasing research in microbiome-based products and their use in treating infectious diseases. Many smaller companies are investing in research, and their major focus is on developing products targeting microbiome modulators for infectious diseases.

Recent Developments:

# In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds.

# In 2018, Enterome entered into a co-development and co-promotion agreement with Takeda for its investigational drug candidate EB8018. This drug is used in patients with Crohn’s disease and has the potential to expand its use to other gastrointestinal (GI) disorders and liver diseases.

# In 2016, 4D Pharma acquired the production assets of Instituto Biomar to expand its clinical and production capabilities of live biotherapeutics.

Europe to account for the largest share of the human microbiome market in 2022

On the basis of region, the global human microbiome market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). Europe is expected to account for the largest share of the global human microbiome market in 2022. The large share of this regional segment is mainly due to the high research activity in this region.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Major Industry Leaders:

The major players in the human microbiome market include Enterome Bioscience (France), E.I. du Pont de Nemours and Company (DuPont) (US), 4D Pharma (UK), and Seres Therapeutics (US).

Various growth strategies have been adopted by these players, such as product launches, agreements, and acquisitions to increase their presence in the global human microbiome market.

Veterinary PoC Diagnostics - Global Industry Leaders & Growth Strategies Adopted by Them

Factors such as increasing prevalence of zoonotic diseases among companion and livestock animals and the growing need for the rapid detection of these diseases, along with the advantages of POCT over laboratory analysis are driving the growth of this market during the forecast period. However, the high cost of veterinary imaging instruments is restraining the growth of this market to some extent.

In 2018, IDEXX Laboratories, Inc. (US) and Zoetis, Inc. (US) dominated the global veterinary point-of-care diagnostics industry, accounting for more than ~80–85% of the total market share.

The global veterinary point-of-care diagnostics market size is projected to reach USD 2.4 billion by 2025 from USD 1.4 billion in 2019, at a CAGR of 8.9%.

The study involved four major activities in estimating the size of the global veterinary point-of-care diagnostics market. Exhaustive secondary research was done to collect information on the adoption of different technologies and their regional adoption trends. Industry experts further validated the data obtained through secondary research through primary research.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105329994

Some of the other prominent players operating in the veterinary point-of-care diagnostics market are Heska Corporation (US), Virbac (France), Thermo Fisher Scientific, Inc. (US), Eurolyser Diagnostica GmbH (Austria), Woodley Equipment Company (UK), Randox Laboratories LTD. (UK), AniPOC, Ltd. (UK), Carestream Health, Inc. (a part of ONEX Corporation) (Canada), NeuroLogica Corporation (a part of Samsung Electronics Co. Ltd.) (South Korea), and FUJIFILM SonoSite (a part of FUJIFILM Holdings Corporation) (Japan).

Recent Developments:

# In 2019, IDEXX Laboratories launched a Canine Progesterone Test for Catalyst Dx and Catalyst One Chemistry Analyzers.

# In 2019, Zoetis, Inc. launched Stablelab, a handheld point-of-care diagnostic blood test for equine.

# In 2019, FUJIFILM SonoSite partnered with Partners Healthcare (US) to enable clinicians to perform scans at point of care.

# In 2019, Eurolyser partnered with Sysmex Corporation (Japan) to sell Eurolyser’s point of care systems measuring CRP.

Zoetis, Inc. (US) dominated the global veterinary point-of-care diagnostics market 2018. The company has a diversified product portfolio, which includes a wide range of point-of-care diagnostic products. IDEXX’s position in the market is attributed to its active R&D activities and wide distribution footprint across the world. To garner a larger share of the market, the company continuously focuses on product developments and launches.

Key Questions Addressed in the Report:

# Who are the top 10 players operating in the global veterinary point-of-care diagnostics market?

# What covers the drivers, restraints, opportunities, and challenges in the veterinary point-of-care diagnostics industry?

# What are the new technological advancements in the veterinary point-of-care diagnostics market?

# Comment on the regulatory scenario for the veterinary point-of-care diagnostics industry in various geographies.

# What are the growth trends in the veterinary point-of-care diagnostics market at the segmental and overall market levels?

IDEXX Laboratories, Inc. (US) accounted for the second-largest share of the veterinary point-of-care diagnostics market in 2018. Its dominance in the market can be attributed to its wide range of product offerings and its strong geographical footprint. In 2018, the company acquired Abaxis, Inc. (US), a pioneer in the veterinary point-of-care diagnostics industry for USD 2.0 billion. The company also focuses on R&D activities to develop its animal health solutions that meet the customers’ demands.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=105329994

By end user, the veterinary clinics segment accounted for the largest share of the veterinary point-of-care diagnostics market in 2018

Based on end user, the market is segmented into veterinary hospitals & academic institutes, veterinary clinics, and home care settings. In 2018, the veterinary clinics segment accounted for the largest share of the market. The large share of this segment is attributed to the growing number of patients visiting vet clinics and the increasing number of private clinical practices.

North America will continue to dominate the market during the forecast period

The market, by region, is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the veterinary point-of-care diagnostics market in 2018. The large share of North America in the global market can be attributed to the increasing adoption of companion animals, growing veterinary healthcare expenditure, and rising demand for animal-derived food products.

Healthcare Claims Management Industry News: Cloud-Based Solutions to Bring Out Major Revolutions

The key factors driving the growth of this market are increasing patient volumes, expanding health insurance market, growing importance of denials management, and declining reimbursement rates.

Target Audience:

# Healthcare insurance companies/payers

# Healthcare IT service providers

# Healthcare institutions/providers

# Venture capitalists

# Healthcare BPO Vendors

# Healthcare KPO Vendors

# Government bodies

# Corporate entities

# Accountable care organizations

The healthcare claims management market is expected to reach USD 13.93 billion by 2023 from an estimated USD 10.77 billion in 2018, at a CAGR of 5.3%.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=36752923

By end user, the healthcare payers segment is expected to command the largest share of the market in 2018

On the basis of end user, the market has been segmented into healthcare payers, healthcare providers, and other end users. The payers segment is expected to command the largest share of the market in 2018. The large share of this segment can be attributed to the mandate for insurance companies to meet the regulatory requirements and reduce unnecessary penalties and punishments.

Major Objectives Behind this Study:

# To define, describe, segment, and forecast the healthcare claims management market by component, delivery mode, type, end user, and region.

# To provide detailed information about factors (drivers, restraints, opportunities, and challenges) influencing healthcare claims management market growth.

# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.

# To forecast the size of the healthcare claims management market segments with respect to North America, Europe, Asia, and the Rest of the World (RoW).

# To strategically analyze the market structure and profile the key players of the global healthcare claims management and comprehensively analyze their core competencies.

# To track and analyze competitive developments such as agreements, collaborations, and partnerships; product deployments, product launches, and enhancements; acquisitions; and expansions in the healthcare claims management market.

North America to dominate the market in 2018

North America is expected to account for the largest share of the healthcare claims management market in 2018, followed by Europe. The large share of North America can be attributed to the high and growing HCIT investments in the region and the presence of regulatory mandates favoring the implementation of healthcare claims management solutions. Also, several major global players are based in the US, owing to which the US has become a center for innovation in the healthcare claims management solutions market.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=36752923

The players that adopted these strategies are Cerner Corporation (US), McKesson Corporation (US), athenahealth (US), eClinicalWorks (US), Optum, Inc, (US), Conifer Health Solutions (US), and nThrive (US).

Product deployments, product launches, & approvals; acquisitions; and partnerships, agreements, and collaborations were the key strategies adopted by key players between 2015 and 2018.

Some of the other players competing in this market are DST Systems (US), Cognizant Technology Solutions (US), Allscripts Healthcare Solutions, Inc. (US), Context 4 Healthcare (US), Health Solutions Plus (US), GE Healthcare (US), RAM Technologies (US), Quest Diagnostics (US), The SSI Group (US), PLEXIS Healthcare Systems (US), and GeBBS Healthcare Solutions (US).

Clinical Trial Management Systems Industry - Technological Innovations to Bring Major Changes

Market Dynamics:

Factors such as significant partnerships between biopharma companies and CROs, rising number of clinical trials, availability of advanced CTMS solutions, growing customer base for CTMS solutions, and rising government funding & grants to support clinical trials are driving the overall demand for CTMS across key markets.

The global clinical trial management system (CTMS) market is expected to reach USD 1,065.6 million by 2022 from USD 590.0 million in 2017, at a CAGR of 12.6%.

However, budget constraints and limited awareness among researchers about the advantages of CTMS solutions are the major factors restraining the growth of CTMS market.

Driver: Rising number of clinical trials to drive the CTMS market

The life science industry is witnessing a global increase in the number of clinical trials each year. This growth in the number of clinical trials conducted can be attributed to factors such as the rapidly increasing aging population, high prevalence of chronic diseases, expiry of blockbuster drugs, availability of government funds for clinical trials, and fierce competition in the pharmaceutical industry. According to ClinicalTrials.gov, as of December 06, 2017, 260,848 clinical trials were registered across the globe.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=470

Recent Developments:

# In November 2017, Bio-Optronics and Complion entered into a partnership in order to integrate and develop their solutions, namely, CTMS and eRegulatory Solutions.

# In September 2017, Pamplona completed the acquisition of Paraxel and bought its shares in order to help PARAXEL increase its productivity.

# In May 2017, Oracle opened its Oracle Cloud EU Region in Germany, with the addition of modern infrastructure as a service (IaaS) architecture and new IaaS and platform as a service (PaaS) cloud services.

# In January 2017, MedNet Solutions released the latest version of iMedNet with enhanced features.

# In June 2016, Bio-Optronics launched the latest version of the Clinical Conductor CTMS.

The pharmaceutical and biopharmaceutical companies segment is expected to hold the largest share of the market in 2017

By end user, the CTMS market is segmented into pharmaceutical and biopharmaceutical companies, contract research organizations, medical device companies, and others. The pharmaceutical and biopharmaceutical companies segment is further subsegmented into large pharmaceutical companies and mid-small pharmaceutical companies. The pharmaceutical and biopharmaceutical companies segment is expected to account for the largest share of the CTMS market in 2017. The largest share is attributed to the increasing adoption of CTMS software during drug clinical trials by pharmaceutical and biopharmaceutical companies.

Key questions addressed in the report:

# What are the growth opportunities related to CTMS market across major regions in the future?

# Emerging countries have immense opportunities for the growth and adoption of enterprise CTMS products. Will this scenario continue in the next five years?

# What are the various types of CTMS products and their market share in the overall market?

# What are the new trends and advancements in the clinical trials industry?

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=470

North America is expected to dominate the CTMS market during the forecast period

Geographically, the CTMS market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America is expected to account for the largest share of the global CTMS market during the forecast period (2017-2027). Factors such as rising number of on-going clinical trials (especially in the US), presence of leading players from both demand and supply sides, and government funding for clinical research are contributing to the large share of the North American region.

Key Market Players:

As of 2016, the global clinical trial management systems market was dominated by Oracle Corporation (US), Medidata Solutions, Inc. (US), PAREXEL International Corporation (US), Bioclinica. (US), Bio-Optronics, Inc. (US), IBM (US), DATATRAK (US), Veeva Systems (US), DSG (US), MasterControl (US), ERT (US), Forte Research Systems (US), MedNet Solutions (US), ArisGlobal (US), and DZS Software Solutions (US).

Specimen Retrieval Market - Growth Potential of Emerging Economies

The study involved four major activities in estimating the current size of the specimen retrieval systems market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain through primary research.

Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

The specimen retrieval systems market is expected to grow from USD 230 million in 2019 to USD 290 million by 2024, at a compound annual growth rate (CAGR) of 4.7% during the forecast period.

Growth in this market is mainly driven by the increasing prevalence of diseases requiring surgical treatment, especially laparoscopic surgeries. However, the high cost of specimen retrieval systems is a major challenge for this market, particularly in emerging countries.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=126359758

Major Objectives Behind This Study:

# To define, describe, and forecast the specimen retrieval systems market by type, introducer size, application, end user, and region.

# To forecast the revenue of the market segments with respect to four main regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW).

# To identify the micromarkets with respect to drivers, industry-specific challenges, opportunities, and trends affecting the growth of the market.

# To analyze market segments and subsegments with respect to individual growth trends, prospects, and contributions to the overall market.

# To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.

# To profile the key players and comprehensively analyze their market shares and core competencies, in terms of market developments and growth strategies.

# To track and analyze competitive developments such as partnerships, agreements, collaborations, acquisitions, product launches, and R&D activities in the specimen retrieval systems market.

Hospitals were the largest end users of specimen retrieval systems in 2018

By end user, the specimen retrieval systems market is segmented into hospitals and other end users. The hospitals segment accounted for the largest market share in 2018 and is expected to register the highest growth during the forecast period. The large share and high CAGR of this segment can be attributed to the robust infrastructure and presence of skilled professionals in hospitals, which has driven the preference for hospital-based treatment.

Recent developments:

# In 2018, Genicon, Inc. entered into a distribution agreement with Greenpine Pharma, China to distribute its complete range of products in China.

# In 2017, B. Braun opened five new production and administration facilities in Penang to cater to end users in Malaysia. The company aims to manufacture medical devices for infusion therapy, pharmaceutical solutions, and surgical instruments in these facilities.

North America commanded the largest share of the specimen retrieval systems market in 2018

North America dominates the specimen retrieval systems market. The large share of North America in this market can be attributed to the increasing incidence and prevalence of cancer, hernia, and appendectomy and the availability of reimbursement for laparoscopic surgeries in the region.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=126359758

The major players operating in this market are Johnson & Johnson Services, Inc. (US), Teleflex Incorporated (US), Applied Medical Resources Corporation (US), CONMED Corporation (US), Cooper Surgical, Inc. (US), Genicon (US), B. Braun Melsungen AG (Germany), Laprosurge (UK), Purple Surgical (UK), and Medtronic (Ireland).

The specimen retrieval systems market is highly consolidated in nature, with a few players offering a variety of products.

The key growth strategies followed by most companies in the specimen retrieval systems market are acquisitions and agreements. These two strategies accounted for the largest share of the overall growth strategies mapped from 2015 to 2018.

Key questions addressed in the report:

# What are the growth opportunities in the specimen retrieval systems market across major regions in the future?

# Emerging countries have immense opportunities for the growth and adoption of specimen retrieval systems. Will this scenario continue during the next five years?

# Where will all the advancements in products offered by various companies take the industry in the mid- to long-term?

# What are the various specimen retrieval systems and their respective market shares in the overall market?

# What are the new trends and advancements in the specimen retrieval systems market?

Nerve Monitoring System Market - Major Industry Leaders & Their Global Growth Contribution

The factors driving the growth of this market are the expansion in target patient base, rising demand for surgical intervention among trauma cases rising, clinical benefits associated with nerve monitoring systems, and the growing availability of medical reimbursements for nerve monitoring in developed nations.

The Global Nerve Monitoring System Market is projected to reach USD 1.45 Billion by 2022 from USD 1.14 Billion in 2017, at a CAGR of 4.9% during the forecast period.

Analysis of the market developments between 2015 and 2017 revealed that several growth strategies such as product launches, acquisitions, mergers, and expansions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the nerve monitoring system market. Among these business strategies, mergers and acquisitions, were the most widely adopted growth strategies by players to strengthen their product portfolios and to remain competitive in the market.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155669000

Medtronic (Ireland) held the leading position in the global nerve monitoring systems market in 2016. The company offers Intraoperative NIM nerve monitoring systems that provide audio and visual warnings to surgeons for various procedures such as ENT, biopsy, neuroendoscopy, and general surgeries.

Target Audience:

# Nerve monitoring product manufacturers

# Nerve monitoring product suppliers and distributors

# Contract manufacturers

# Healthcare service providers

# Research laboratories and academic institutes

# Clinical research organizations (CROs)

# Government regulatory authorities

# Independent associations and non-government organizations

# National and international regulatory authorities

# Market research firms

This is helping the company to strengthen its position in the nerve monitoring market. The company is increasingly focusing on research and development activities to maintain its product portfolio. For instance, the company invested USD 1,640 million in research and development activities in 2015, whereas it invested USD 2,193 million in 2017.

NuVasive (US) secured the second position in the global nerve monitoring system market in 2016. The company is focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions. The company’s nerve monitoring system “NVM5 platform” is capable of performing various functions during spine surgery such as nerve avoidance and navigation, nerve monitoring and instrument navigation, spinal cord monitoring, peripheral sensory nerve monitoring, computer-assisted, rod-bending technology, and intraoperative angular assessment tools.

Key Questions Addressed by This Report:

# What are the business growth strategies adopted by key market players to maintain their market position across key geographies?

# What is the existing developmental pipeline of major nerve monitoring systems among Medtech manufacturers as well as academia?

# Growing number of trauma based surgical procedures is a key trend in clinical management. What impact trauma based surgical procedures will have on nerve monitoring systems market during the forecast period?

# What alternative technologies/therapies are currently being used for nerve monitoring worldwide? What competition they pose for key nerve monitoring systems market players.

The company is continuously focusing on significant research and development efforts to expand its product platforms and develop advanced applications of unique technology into procedurally integrated surgical solutions.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=155669000

North America accounted for the largest share of the nerve monitoring system market

Geographically, the nerve monitoring system market is segmented into North America, Europe, Asia, and the Rest of the World. North America is estimated to account for the largest share of the market in 2017, which is driven by the presence of a large patient population accompanied by a well established medical reimbursement policy.

Based on end user: 

The nerve monitoring systems market is segmented into hospitals and surgical centers, and ambulatory surgical centers. The hospitals and surgical centers segment is projected to be the fastest-growing end-user segment of the nerve monitoring system market. High growth rate of the hospitals and surgical centers segment can be attributed to factors such as increasing number of complex surgical procedures performed there, rising number of diagnostic and surgical procedures carried out at hospitals, and growing number of hospitals and surgical centers across developing countries (such as India, China, Poland, Mexico, and South Africa)

Ablation Technology Market - Emerging Industry Dynamics | Technological Innovations & Future Forecasts

Emergence of next-generation ablation products and technologies, rising incidence of cancer, growing prevalence of cardiovascular diseases and increasing number of ablation procedures are the major factors driving the growth of the ablation technologies market during the forecast period.

The global ablation technology market is estimated to be valued at USD 2.82 billion in 2016 and is expected to reach USD 4.73 billion by 2021, growing at a CAGR of 10.9% between 2016 and 2021.

Key questions addressed in the report:

# What are the growth opportunities related to ablation technologies market across major regions in the future?

# Emerging countries have immense opportunities for the growth and adoption of ablation technologies products. Will this scenario continue in the next five years?

# What are the various ablation technologies product segments and their market share in the overall market?

# What are the new trends and advancements in the ablation technologies market?

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=791

Cardiovascular diseases form the largest and fastest-growing application segment of the ablation technologies market

By application, the ablation technologies market is segmented into cardiovascular disease, pain management, cancer, ophthalmology, cosmetic surgery, gynecology, urology, orthopedics, and other applications. Cardiovascular diseases accounted for the largest share of the ablation technologies market in 2016 and are anticipated to witness the highest growth during the forecast period. The high incidences of CVDs across the globe and technological advancements in cardiac ablation devices are supporting the growth of the ablation technologies market for this application segment.

Recent Developments:

# In August 2016, Biosense Webster, Inc. launched its THERMOCOOL SMARTTOUCH SF Catheter in the U.S. for the treatment of drug resistant paroxysmal atrial fibrillation. This helped the company to expand its product portfolio and increase its revenue base in the U.S.

# In May 2016, Galil Medical Inc. was acquired by the BTG plc group (a part of BTG International Ltd, U.K.); for a value of USD 110.0 million. BTG International is prominent manufacturer of cryoablation products and possesses strong product distribution network across Europe.

# In October 2016, Smith & Nephew established a new a sports medicine orthopedic devices manufacturing facility at Costa Rica with an investment of USD 55 million. This helped the company strengthen its product manufacturing capabilities and address the growing demand for ablation products in the ablation technologies market.

# In December 2015, Medtronic entered into a partnership with Baylis Medical (Canada) to increase patient access to its OsteoCool RF Ablation System and further innovation in the system. Medtronic had acquired the OsteoCool technology and related IP from Baylis Medical in December 2015.

# In April 2016, Abbott Laboratories and St. Jude Medical, Inc. entered into a merger agreement. As per the agreement Abbott will acquire St. Jude Medical by end of the 2016. This acquisition is expected to increase the global presence and capabilities of both the companies and diversify their product offerings in the medical devices industry.

The radiofrequency ablation segment will continue to dominate the ablation technologies market, by type, during the forecast period

Based on type, the ablation technologies market is categorized into laser/light, radiofrequency, ultrasound, electrical, cryoablation, microwave, and hydrothermal ablation technologies. The radiofrequency ablation segment accounted for the largest share of the ablation technologies market in 2016. This is majorly due to the lower cost of radiofrequency ablation procedures as compared to the other ablation techniques. Also, radiofrequency ablation is preferred due to its safety, efficacy, and ease of use.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=791

Dominant market players such as Medtronic, Inc. (U.S.), St. Jude Medical, Inc. (U.S.), Boston Scientific Corporation (U.S.), and CONMED Corporation (U.S.), have introduced several advanced radiofrequency ablation devices during 2013 to 2016 to keep pace with the industry trends.

Major strategic developments are taking place in the field of radiofrequency ablation technology, which exhibits high growth potential in the near future.

European Hemostats & Sealants - Expected Technological Innovations & Future Forecasts

The growth of this market is majorly driven by the launch of new products and favorable reimbursement scenario. However, the shift toward minimally invasive surgeries and adverse effect of hemostats are the major factors restraining the growth of this market.

The European hemostats and sealants market is projected to reach USD 89 million by 2024 from USD 63 million in 2019, at a CAGR of 7.0%.

The study involved four major activities to estimate the current size of the hemostats and sealants (focused brands) market. Exhaustive secondary research was conducted to collect information on the market and its different subsegments.

The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=115823197

Report Objectives:

# To define, describe, and forecast the European hemostats and sealants market (by value) on the basis of focused brand and country.

# To identify micromarkets and the drivers, restraints, industry-specific challenges, opportunities, and trends affecting the growth of the focused brands market.

# To profile focused brands and comprehensively analyze their market shares in focused European countries

Based on focused products, Tachosil is projected to register the highest growth during the forecast period

Based on focused products, the market is segmented into Tachosil, Lyostypt, Sangustop, Veriset, Avitene, and Hemopatch. Tachosil is expected to grow at the highest CAGR during the forecast period, mainly due to the increasing demand for this product among end users.

Germany commands the largest share of the market

Based on region, the hemostats and sealants (focused products) market is segmented into Germany, the UK, France, Italy, and Spain. Germany dominates the hemostats and sealants market due to its large patient population and the favorable reimbursement scenario for the usage of hemostats.

Key questions addressed in the report:

# What are the growth opportunities in the hemostats and sealants market across major countries in Europe in the future?

# What are the key drivers and restraints in the hemostats and sealants market?

# What are the key brands in the hemostats and sealants market?

# Which are the key countries in the hemostats and sealants market?

# What are the most preferred brands amongst end users?

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=115823197

The market for hemostats and sealants is anticipated to grow mainly due to the launch of the new products, M&A’s, and favorable reimbursement scenario in Europe. However, the increasing preference for minimally invasive surgeries and the reducing preference for the usage of hemostats while performing surgeries are expected to hinder the growth of this market during the forecast year.

Key players operating in the hemostats and sealants (focused products) market include B. Braun (Germany), Medtronic (Ireland), C. R. Bard (US), Takeda (Japan), and Baxter (US).

Molecular Biology Enzymes Market to Grow at a Healthy Rate in Near Future

Target Audience:

# Molecular Biology Enzymes and Kits & Reagents Manufacturers and Vendors

# Associations Related to Molecular Biology Enzymes and Kits & Reagents

# Contract Research Organizations (CROs)

# Research Institutes and Academic Centers

# Pharmaceutical and Biopharmaceutical Companies

# Business Research and Consulting Service Providers

# Venture Capitalists

The global molecular biology enzymes and kits & reagents market is projected to reach USD 13.60 Billion by 2022 from USD 6.52 Billion in 2017, at a CAGR of 15.8% during the forecast period.

The key factors driving the growth of this market include increased research activities and R&D investments in the life science industry, rising number of genome projects, technological advancements in the life science industry, and rising incidence of infectious diseases and genetic disorders. However, the privacy concerns related to genetic information and limited reimbursements for genetic testing may hinder the growth of this market to a certain extent.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164131709

By application, the polymerase chain reaction (PCR) segment to hold the largest market share in 2017

Based on application, the market is segmented into polymerase chain reaction (PCR), sequencing, cloning, epigenetics, restriction digestion, synthetic biology, and other applications (mutagenesis, in vitro transcription, and molecular labeling & detection). The polymerase chain reaction (PCR) segment is expected to command the largest share of the molecular biology enzymes and kits & reagents market in 2017. The large share of this segment can be attributed to the low cost of PCR equipment, use of PCR equipment by the majority of the end users, and increasing use of PCR for molecular diagnostic assays in hospitals and clinics.

North America to dominate the market in 2017

In 2017, North America is expected to account for the largest share of the molecular biology enzymes and kits & reagents market, followed by Europe, Asia Pacific (APAC), and the Rest of the World (Latin America and the Middle East & Africa). Factors such as increasing research funding for genomics research, rising number of pharmaceutical and biotechnology companies, favorable reimbursement scenario for molecular diagnostics, and growing prevalence of target indications are contributing to the large share of North America.

The molecular biology enzymes and kits & reagents market in several APAC countries, particularly, China, Japan, and India, are expected to witness high growth during the forecast period. This can be attributed to the increasing government interest in biomedical and biotechnology industries, outsourcing of clinical research activities to China, involvement of industry players in the Japanese market, growing pharmaceutical industry in India backed by government initiatives to drive market growth, and initiatives by non-profit organizations.

By product, the kits & reagents segment to account for the largest share of the market in 2017

On the basis of product, the molecular biology enzymes and kits & reagents market is segmented into enzymes and kits & reagents. In 2017, kits & reagents segment is expected to account for the largest share of the global market. The large share of this segment can be primarily attributed to the requirement of repeat purchase of these single-use products and increasing drug research in the pharmaceutical industry. The enzymes market is further subsegmented into polymerases, ligases, restriction endonucleases, reverse transcriptases, phosphatases, proteases & proteinases, and other enzymes. In 2017, the polymerases enzymes segment is expected to account for the largest share of the enzymes market.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=164131709

By end user, academic & research institutes to hold the largest market share in 2017

Based on end user, the market is segmented into academic & research institutes, hospitals & diagnostic centers, pharmaceutical & biotechnology companies, and other end users (contract research organizations (CROs), food & beverage companies, and forensic agencies). The academic & research institutes segment is expected to command the largest share of the molecular biology enzymes and kits & reagents market in 2017. The large share of this segment can be attributed to the increasing research activities backed by funding from government and private organizations.

The key players in the global molecular biology enzymes and kits & reagents market are Thermo Fisher (US), Merck (Germany), Illumina (US), QIAGEN (Netherlands), New England Biolabs (US), Promega (US), Agilent (US), Roche (Switzerland), Takara Bio (Japan), Bio Basic (Canada), Jena Bioscience (Germany), and Molecular Biology Resources (US).

Healthcare Cloud Computing Market is Expecting major Revenue Growth in Near Future

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

The global healthcare cloud computing market size is projected to reach USD 51.9 billion by 2024, from an estimated USD 23.4 billion in 2019 at a CAGR of 17.2 % during the forecast period.

The growth of this market is primarily attributed to the increasing adoption of big data analytics, wearable devices, and IoT in healthcare and the advantages of cloud usage, such as improved storage, flexibility, and scalability of data.

Critical Questions Answered in the Report:

# How will the current technological trends affect the healthcare cloud computing market in the long term?

# What are the reasons contributing to the growth of the provider and payer solutions in the market?

# Which regions are likely to grow at the highest CAGR in the global market?

# What are the challenges hindering the adoption of healthcare cloud computing in the market?

# What are the growth strategies being implemented by major market players?

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=347

By component, the services segment accounted for the largest share of the market in 2018

Based on the component, the market is categorized into software and services. The services segment commanded the largest share of the healthcare cloud computing market during the forecast period. This can be attributed to the recurring nature of services such as training and education, installation, software upgrades, consulting, and maintenance.

By pricing model, the pay-as-you-go segment accounted for the largest share of the market in 2018

Based on the pricing model, the market is categorized into pay-as-you-go and spot pricing. The pay-as-you-go segment commanded the largest share of the healthcare cloud computing market in 2018. The large share of this segment can be attributed to the fact that the pay-as-you-go model allows healthcare providers to provide the latest software solutions while keeping operating costs to a minimum. This helps healthcare providers not to lock-in their capital on purchasing equipment, such as CPUs and servers, but utilizing all these services on an on-demand basis by paying only for what they use.

Recent Developments:

# In 2019, NTT DATA and Google Cloud announced a joint go-to-market strategy to provide consulting, implementation, and managed services to clients seeking digital transformation. Google Cloud enhanced NTT DATA’s cloud transformation offerings by adding more Google Cloud resources in analytics, artificial intelligence, machine learning, cloud migration, IoT, security, and productivity.

# In 2019, IBM acquired Red Hat, which is a landmark acquisition for USD 34 billion. The addition will enhance IBM’s hybrid cloud portfolio and aim to develop a next-generation multi-cloud hybrid platform.

# In 2018, DXC Technologies acquired TESM (UK) to expand the range of cloud-based solutions and enterprise software as a service solution. This enabled DXC to address customer needs across the Europe region.

By service model, the software-as-a-service segment accounted for the largest share of the market in 2018

Based on the service model, the market is categorized into software-as-a-service, infrastructure-as-a-service, and platform-as-a-service. The software-as-a-service segment commanded the largest share of the healthcare cloud computing market in 2018. The large share of this segment can be attributed to the fact that SaaS was introduced in the market well in advance of the other two models. Additionally, the SaaS model offers several advantages, such as lower total cost of ownership (TCO) compared to on-premise solutions, faster deployment time, and limited up-front capital expenses. The IaaS segment is expected to grow at the highest CAGR owing to its advantages, such as needing any upfront charges, bandwidth utilization fees, or minimum term commitments.

North America dominated the market in 2018

In 2018, North America accounted for the largest share of the global healthcare cloud computing market, followed by Europe. Factors such as the increasing adoption of Electronic Health Records (EHRs) among medical professionals, the incentive-driven approach of government health IT programs, and active participation by private sector players in industry development contribute to the largest share of this region.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=347

Some players operating in the global healthcare cloud computing market include IBM (US), Carestream Health, Inc (US), athenahealth (US), CareCloud Corporation (US), Siemens Healthineers (Germany), eClinicalWorks (US), Koninklijke Philips (Netherlands), Allscripts Healthcare Solutions, Inc (US), GE Healthcare (US), and Dell, Inc. (US), among others.